Clinical-stage biopharmaceutical company developing targeted radiopharmaceuticals, especially theranostic targeted radionuclide therapies (TRT) for cancer and other serious diseases
Clinical-stage biopharmaceutical company developing targeted radiopharmaceuticals, especially theranostic targeted radionuclide therapies (TRT) for cancer and other serious diseases. Its platforms cover targeted ligand screening, radiopharmaceutical conjugation, and clinical translation, with multiple drug candidates in development.